-
Sign In
- Sony Biotechnology
- Sony Biotechnology
A future of long-term, minimally toxic immunotherapy personalized to the cellular level is on the horizon—but only if manufacturers have the means to produce these therapies within a GMP environment.
Watch this webinar to discover how the CGX10 Cell Isolation System can bring the future of immunotherapy closer to today. This purpose-built, GMP-ready solution performs multiparametric cell isolation in a single step, for a smooth path from clinical to commercial manufacturing for these breakthrough treatments.
The CGX10 Cell Isolation System from Sony is a unique fully GMP-ready cell sorting instrument with “closed” single unit disposables. It uses fluorescence-activated cell sorting for multiparametric isolation of rare and desired target cell types.
Join us to learn about the CGX10 Cell Isolation System’s benefits and features, and to gather insights into the validation data generated during a comprehensive assessment of the CGX10. This assessment was completed in a true grade B GMP environment at the Centre for Commercialization of Regenerative Medicine (CCRM), in Toronto, Canada.
Learning Objectives:
This webinar will provide insights to professionals working in cell and gene therapy development and the clinical grade manufacturing space who want to learn more about the CGX10 Cell Isolation System and explore the features which make it suitable for use in a true grade B GMP environment.
Jerry Barnhart has been working in the field of flow cytometry for nearly 25 years. In this period, he has had a variety of different roles including core lab manager in both academic and industry settings, technical sales, and field applications support. He is currently the manager of the field application specialist team at Sony Biotechnology. Jerry's current focus is on spectral flow cytometry analysis and cell sorting, as well as support of cell therapy product manufacturing workflows using the CGX10 Cell Isolation System.
Manoja Eswara is a Senior Development Manager at CCRM in Toronto. At CCRM, Manoja is engaged in management and execution of contract services for academic and industrial clients, specializing in the areas of gene editing, iPSC reprogramming, differentiation and scale up and Immunotherapy. She is also engaged in technology evaluation, translation, process development and tech transfer to GMP, in the fields of cell and gene therapy. Prior to CCRM, Dr. Eswara did her postdoctoral fellowship at Lunenfeld-Tanenbaum Research Institute, Toronto, studying the role of histone chaperones in cancer epigenetics. Dr. Eswara received her PhD in molecular biology from the University of Guelph.